Biofarm (BSE:BIO) FFO


BSE:BIO Biofarm SA BSE:BIO
69 GF Score
Price lei1.37
GF Value lei0.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm FFO?

FFO (Funds from operations) only applies to REITs.

BSE:BIO
69GF Score
Biofarm SA BSE:BIO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.37 is trading 57.5% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • FFO:
  • GF Value™: lei0.87 vs. price of lei1.37 (57.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for BSE:BIO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.37
Price
lei0.87
GF Value